Sign in

You're signed outSign in or to get full access.

Wilbur Ross

Director at Coya Therapeutics
Board

About Wilbur Ross

Wilbur L. Ross, Jr. (age 87) is an independent Class I director of Coya Therapeutics, serving since November 2023 with a term continuing until the 2026 annual meeting. He is the former U.S. Secretary of Commerce (2017–2021) and previously Chairman and Chief Strategy Officer of WL Ross & Co. LLC, with over five decades of investment banking and private equity experience. He holds an undergraduate degree in English literature from Yale University and graduated with distinction from Harvard Business School .

Past Roles

OrganizationRoleTenureCommittees/Impact
U.S. Department of Commerce39th Secretary of CommerceFeb 28, 2017 – 2021Principal voice of business in the Administration; focus on tools for entrepreneurs and jobs
WL Ross & Co. LLCChairman & Chief Strategy OfficerMulti-decadeRestructured >$400B of assets across diverse industries; chair/lead director for >100 companies

External Roles

OrganizationRoleTenureNotes
Japan SocietyChairmanNot specifiedPhilanthropic leadership
Brookings InstitutionTrustee; Chair of Economic Studies CouncilNot specifiedPolicy and economic studies engagement
Musée des Arts Décoratifs (Paris)International Counsel MemberNot specifiedCultural institution support
Blenheim FoundationTrusteeNot specifiedPhilanthropy
American Friends of the Rene Magritte Museum (Brussels)PresidentNot specifiedArts patronage
Palm Beach Civic AssociationDirectorNot specifiedCommunity leadership
Yale School of ManagementAdvisory Board MemberNot specifiedAcademic advisory role

Board Governance

  • Independence: The Board determined Ross is independent under Nasdaq and SEC rules .
  • Committees: Audit Committee (Dov Goldstein, Chair; Dieter Weinand; Ann Lee) ; Compensation Committee (Anabella Villalobos, Chair; Dov Goldstein; Ann Lee) ; Nominating & Corporate Governance (Dieter Weinand, Chair; Dov Goldstein; Anabella Villalobos) . Ross is not listed on any standing committee .
  • Attendance: In FY2024 the Board met 5 times; other than Mr. Ross, each director attended at least 75% of Board meetings. This indicates Ross attended less than 75% of meetings (RED FLAG) .
  • Tenure on Board: Director since 2023; Class I term continues until 2026 .
  • Anti-hedging: Company policy prohibits hedging/monetization transactions like zero-cost collars and forward sales (alignment positive) .

Fixed Compensation

YearCash Retainer ($)Committee Fees ($)Stock Awards ($)Option Awards ($)Total ($)
202440,000 0 (no committee service) 0 55,850 95,850
  • Non-Employee Director Compensation Policy (structure): Annual retainer $40,000; Chairman (if non-employee) $60,000; Committee chair/member fees: Audit $15,000/$7,500; Compensation $10,000/$5,000; Nominating & Governance $7,500/$3,750. Compensation may be made in stock options at Board’s discretion .

Performance Compensation

Equity ComponentGrant MechanicsTypical Grant SizeVestingNotes
Non-employee director optionsAutomatic upon joining; and each Jan 1 while serving10,000 shares on joining; 10,000 shares annuallyFully vests on 1-year anniversary; 10-year term; strike at 100% FMV on grant dateGranted under 2021 Incentive Plan

Vested vs Unvested Options (as of May 6, 2025):

  • Options exercisable within 60 days: 10,000
  • Options not exercisable within 60 days: 10,000

Other Directorships & Interlocks

  • Current public company boards: Not disclosed in the proxy for Ross; biography notes past service as chair/lead director at >100 companies across >20 countries (historical breadth, no current interlocks identified at COYA) .
  • Committee roles at other public companies: Not disclosed .

Expertise & Qualifications

  • Deep restructuring and turnaround expertise; elected to both the Private Equity Hall of Fame and Turnaround Management Hall of Fame .
  • Recognitions: Bloomberg Markets “50 most influential in global finance”; international awards from South Korea (financial crisis support) and Japan (Order of the Rising Sun) .
  • Education: Yale (BA, English); Harvard Business School (graduated with distinction) .

Equity Ownership

HolderCommon SharesOptions Exercisable ≤60 DaysOptions Not Exercisable ≤60 DaysTotal Beneficial Ownership% of Shares Outstanding
Wilbur L. Ross165,016 10,000 10,000 175,016 1.1%
  • Ownership basis: Percentage calculated on 16,724,998 shares outstanding (Record Date May 6, 2025) and in accordance with SEC beneficial ownership rules .

Governance Assessment

  • Independence and alignment: Ross is independent under Nasdaq/SEC standards . He holds a meaningful personal stake (1.1%) plus options, which supports alignment with shareholders .
  • Engagement risk: Attendance below 75% in FY2024 is a notable governance red flag for board effectiveness; it may signal limited engagement or availability (particularly concerning for a small-cap biotech requiring active oversight) .
  • Committee influence: Absence from all standing committees limits direct involvement in audit oversight, compensation design, and governance/nominations—a potential effectiveness gap relative to peers .
  • Pay structure: Director compensation is modest in cash ($40k) with equity delivered as stock options; no meeting fees or stock awards reported for 2024, and no committee fees given lack of committee membership, which limits pay complexity and potential conflicts .
  • Policies and controls: Anti-hedging policy is in place (positive alignment) ; indemnification agreements typical for Delaware corporations ; related-party transaction policy assigns oversight to Audit Committee (no related-party transactions disclosed involving Ross) .
  • Section 16 compliance: Late filing notices in 2024 involved other directors (Villalobos, Lee, Weinand, Goldstein); Ross was not identified in the late filings disclosure .

RED FLAGS

  • Board meeting attendance below 75% in FY2024 (engagement concern) .
  • No committee membership (reduced governance influence) .

Neutral/Positive Signals

  • Independence affirmed .
  • Personal share ownership (1.1%) plus options .
  • Anti-hedging policy prohibits hedging/monetization .

Missing/Not Disclosed

  • Director-specific stock ownership guidelines and compliance status .
  • Any pledging of shares (no disclosure identified) .
  • Current public-company board interlocks pertinent to COYA’s ecosystem .

Implications for investors

  • Ross brings seasoned restructuring and policy experience but limited recent attendance and no committee roles may diminish board-level operational oversight. Ownership alignment is reasonable; however, monitoring future attendance and any elevation into committee roles would be prudent to assess ongoing governance effectiveness .